



Sage Therapeutics to Present at Morgan Stanley Healthcare Conference

September 7, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 7, 2017-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2017 at 8:45 a.m. ET in New York, NY.

A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, brexanolone (SAGE-547), is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170907006533/en/>

Source: Sage Therapeutics

Investor Contact:

Sage Therapeutics
Paul Cox, 617-299-8377
paul.cox@sagerx.com

or

Media Contact:

Suda Communications LLC
Maureen L. Suda, 585-387-9248
maureen.suda@sagerx.com